Finally, gefitinib 53 acts as a PLK1 kinase inhibitor, and it induces pyroptosis in esophageal squamous cell carcinoma (ESCC) and various other cancer types by triggering caspase-3, GSDME, and Bax activation [168] (Fig. 10). Here, GSDME is linked to cancer.